Avillion Life Sciences has confirmed that AstraZeneca’s Airsupra can reduce the risk of severe exacerbations in patients with persistent asthma.
The Phase IIIb BATURA trial evaluated the albuterol and budenoside combination, finding that it met its primary endpoint when used as a rescue medication in response to symptoms.
Avillion conducted the clinical trial under an exclusive co-development agreement with AstraZeneca, and the data will soon be shared with regulatory authorities.
Airsupra is the first and only anti-inflammatory rescue medication for the prevention of bronchoconstriction, and is suitable for patients with asthma who are 18+.
The inhaled therapeutic has already received approval from the US FDA based on the results of the MANDALA and DENALI Phase III trials, which were also ran by Avillion.
It is currently also being studied in adolescents with asthma in the ACADIA Phase III trial.
CEO of Avillion, Allison Jeynes, commented: “We are thrilled with this positive outcome from the BATURA trial, which has generated outstanding clinical results. Our work together in bringing this new therapy to asthma patients really highlights the strong value proposition of our clinical co-development model, as well as the clinical and operational excellence that our highly committed international team brings.”
AstraZeneca's Executive Vice President of BioPharmaceuticals, Sharon Barr, added: “The impressive BATURA trial results add to the body of evidence supporting Airsupra as a first-in-class rescue treatment and its role in reducing the risk of asthma exacerbations in patients regardless of their disease severity and reducing the need for systemic corticosteroids.”
